Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Cash from Investing Activities (2021 - 2025)

SAB Biotherapeutics' Cash from Investing Activities history spans 5 years, with the latest figure at -$1.7 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 118.29% year-over-year to -$1.7 million; the TTM value through Dec 2025 reached -$121.7 million, down 917.42%, while the annual FY2025 figure was -$121.7 million, 917.42% down from the prior year.
  • Cash from Investing Activities reached -$1.7 million in Q4 2025 per SABSW's latest filing, up from -$129.9 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $11.2 million in Q2 2024 to a low of -$129.9 million in Q3 2025.
  • Average Cash from Investing Activities over 5 years is -$7.3 million, with a median of -$365293.0 recorded in 2022.
  • The largest YoY upside for Cash from Investing Activities was 49556.96% in 2024 against a maximum downside of 147126.32% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$2.4 million in 2021, then skyrocketed by 95.01% to -$117754.0 in 2022, then skyrocketed by 42.37% to -$67864.0 in 2023, then soared by 13849.21% to $9.3 million in 2024, then crashed by 118.29% to -$1.7 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Cash from Investing Activities are -$1.7 million (Q4 2025), -$129.9 million (Q3 2025), and $5.2 million (Q2 2025).